Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390540 | 0.92 | FOLH1 (0.59) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL29894486 | 0.92 | FOLH1 (0.59) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL29669470 | 0.90 | FOLH1 (0.58) | FOLH1GSRRNPEPMMP2MMP9 | |
| Glycine SCHEMBL15676612 | 0.86 | FOLH1 (0.59) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL29396372 | 0.86 | FOLH1 (0.52) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL30901213 | 0.83 | SLC6A5 (0.54) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL28266171 | 0.83 | FOLH1 (0.56) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL29529476 | 0.83 | SLC6A5 (0.54) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL29511950 | 0.83 | FOLH1 (0.75) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL20680677 | 0.81 | FOLH1 (0.58) | FOLH1GSRRNPEPMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025016307-A1 | HEALTH HOMEOSTASIS MODEL, ELASTIC HOMEOSTASIS MODEL, AND USAGE METHOD THEREFOR | 汤臣倍健股份有限公司 | 2025-01-23 | — | — | WO | claimed |
| US-12569431-B2 | Immunostimulatory method | Ena Respiratory Pty Ltd (AU) | 2026-03-10 | — | — | US | disclosed |
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-12234263-B2 | Influenza vaccines | INVVAX, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2025016307-A1 | HEALTH HOMEOSTASIS MODEL, ELASTIC HOMEOSTASIS MODEL, AND USAGE METHOD THEREFOR | 汤臣倍健股份有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240417738-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION | 2024-12-19 | — | — | US | disclosed |
| EP-3600374-B1 | TREATMENT OF RESPIRATORY INFECTION | Ena Respiratory Pty Ltd (AU) | 2024-05-15 | — | — | EP | disclosed |
| EP-3669892-B1 | COMPOSITION FOR USE IN A IMMUNOSTIMULATORY METHOD | Ena Respiratory Pty Ltd (AU) | 2024-05-08 | — | — | EP | disclosed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| US-20230226004-A1 | TREATMENT OF CORONAVIRUS | Ena Respiratory Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| WO-2023135949-A1 | PROTEOGLYCAN-CONTAINING IMMUNE RESPONSE MODIFIER | 一丸ファルコス株式会社 | 2023-07-20 | — | — | WO | disclosed |
| EP-4157255-A1 | TREATMENT OF CORONAVIRUS | Ena Respiratory Pty Ltd (AU) | 2023-04-05 | — | — | EP | disclosed |
| US-20230043518-A1 | CANCER IMMUNOTHERAPY | Axelia Oncology Pty Ltd (AU) | 2023-02-09 | — | — | US | disclosed |
| CN-115501172-A | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-12-23 | — | — | CN | disclosed |
| US-20220296505-A1 | IMMUNOSTIMULATORY METHOD | INNAVAC PTY LTD (AU) | 2022-09-22 | — | — | US | disclosed |
| CN-107249570-B | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-08-09 | — | — | CN | disclosed |
| EP-4025204-A1 | CANCER IMMUNOTHERAPY | Axelia Oncology Pty Ltd (AU) | 2022-07-13 | — | — | EP | disclosed |
| US-11351114-B2 | Immunostimulatory method | Ena Therapeutics Pty Ltd (AU) | 2022-06-07 | — | — | US | disclosed |
| US-20220096627-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS THROUGH STIMULATED INNATE IMMUNITY IN COMBINATION WITH ANTIVIRAL COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043518-A1 | CANCER IMMUNOTHERAPY | TLR2, CD274, PDCD1LG2 | FOLH1 222/4885GSR 1995/4885RNPEP 3642/4885 |
| US-20230226004-A1 | TREATMENT OF CORONAVIRUS | TLR2, TLR3, TLR4 | FOLH1 1402/4885GSR 1793/4885RNPEP 1052/4885 |
| US-11351114-B2 | Immunostimulatory method | TLR2, TLR3, TLR1 | FOLH1 1479/4885GSR 1779/4885RNPEP 1495/4885 |
| US-20220296505-A1 | IMMUNOSTIMULATORY METHOD | TLR2, TLR3, TLR1 | FOLH1 1479/4885GSR 1779/4885RNPEP 1495/4885 |
| US-12569431-B2 | Immunostimulatory method | TLR2, TLR3, TLR1 | FOLH1 849/4885GSR 2629/4885RNPEP 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.